Novartis files patent suit against Biocon over diabetes drug

Novartis has taken Biocon to court for infringing the patent on its diabetes drug Galvus, the Swiss drugmaker said in a statement on Thursday.

The Basel-based firm has filed infringement proceedings and is seeking an injunction against Biocon at Delhi's High Court to try to stop the Indian company launching a generic version of Galvus, also known as vildagliptin.

In a hearing that took place on March 28, the Delhi court ordered that Biocon cannot manufacture, sell or export vildagliptin until the next court hearing, Novartis said in an emailed statement.

Galvus is one of Novartis' best-selling medicines, achieving $1.2 billion of sales last year.


  • EPFO would do well to have better risk management of available cash

    The Employees’ Provident Fund Organisation (EPFO) is apparently revisiting its decision to invest about Rs 6,000 crore in stocks this year.


Stay informed on our latest news!


Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs


Amita Sharma

Smart cities for the smart citizens

The 21st century has been spoken of as the urban ...

Zehra Naqvi

The prejudiced childhood

Sometimes the most unusual things can remind you of the ...

Gautam Gupta

To read about online videos, click here

ONce, not so long ago, exhorbitant costs had made sure ...


William D. Green

Chairman & CEO, Accenture